Skip to main content
. Author manuscript; available in PMC: 2016 Jan 16.
Published in final edited form as: J Cutan Pathol. 2015 Sep 2;42(11):807–814. doi: 10.1111/cup.12564

Fig. 2.

Fig. 2

5-hydroxymethycytosine (5-hmC) immunolabeling is markedly attenuated in both primary and metastatic melanoma when compared with melanocytic nevi. The mean immunohistochemical staining score ± standard deviation for nevi, primary invasive melanoma and metastatic melanoma are shown for both cohorts. *p < 0.001 (two-sided Student’s t-test). n.s., not statistically significant.